T. Rowe Price Associates’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,735
| Closed | -$70K | – | 3063 |
|
|
2024
Q3 | $70K | Hold |
3,735
| – | – | ﹤0.01% | 2884 |
|
|
2024
Q2 | $62K | Sell |
3,735
-525
| -12% | -$8.72K | ﹤0.01% | 2831 |
|
|
2024
Q1 | $74K | Buy |
4,260
+2,387
| +127% | +$41.5K | ﹤0.01% | 2826 |
|
|
2023
Q4 | $30K | Hold |
1,873
| – | – | ﹤0.01% | 2849 |
|
|
2023
Q3 | $93K | Buy |
1,873
+605
| +48% | +$30K | ﹤0.01% | 2679 |
|
|
2023
Q2 | $100K | Buy |
1,268
+132
| +12% | +$10.4K | ﹤0.01% | 2694 |
|
|
2023
Q1 | $103K | Sell |
1,136
-565
| -33% | -$51.2K | ﹤0.01% | 2682 |
|
|
2022
Q4 | $201K | Sell |
1,701
-445
| -21% | -$52.6K | ﹤0.01% | 2531 |
|
|
2022
Q3 | $390K | Sell |
2,146
-54
| -2% | -$9.81K | ﹤0.01% | 2251 |
|
|
2022
Q2 | $197K | Buy |
2,200
+1,005
| +84% | +$90K | ﹤0.01% | 2603 |
|
|
2022
Q1 | $185K | Buy |
1,195
+300
| +34% | +$46.4K | ﹤0.01% | 2724 |
|
|
2021
Q4 | $266K | Buy |
+895
| New | +$266K | ﹤0.01% | 2643 |
|